Bright Minds Biosciences (DRUG) Projected to Post Quarterly Earnings on Thursday

Bright Minds Biosciences (NASDAQ:DRUG) is projected to issue its Q1 2026 results before the market opens on Thursday, February 12th. Analysts expect Bright Minds Biosciences to post earnings of ($0.98) per share for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 12:30 PM ET.

Bright Minds Biosciences Stock Down 0.2%

NASDAQ:DRUG opened at $76.00 on Thursday. The firm has a market cap of $739.48 million, a PE ratio of -62.30 and a beta of -6.18. The company’s 50-day moving average price is $82.69 and its two-hundred day moving average price is $61.14. Bright Minds Biosciences has a 12 month low of $23.17 and a 12 month high of $123.75.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Bright Minds Biosciences in a research note on Monday, December 1st. Chardan Capital restated a “buy” rating and set a $80.00 price objective on shares of Bright Minds Biosciences in a report on Friday, January 2nd. HC Wainwright reiterated a “buy” rating and issued a $115.00 target price on shares of Bright Minds Biosciences in a report on Tuesday, December 30th. Robert W. Baird set a $142.00 price objective on Bright Minds Biosciences in a research note on Wednesday, January 7th. Finally, Zacks Research downgraded Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 2nd. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Bright Minds Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $121.00.

Hedge Funds Weigh In On Bright Minds Biosciences

Several hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new position in Bright Minds Biosciences in the third quarter valued at approximately $58,000. JPMorgan Chase & Co. boosted its holdings in shares of Bright Minds Biosciences by 624.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company’s stock valued at $57,000 after buying an additional 1,873 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Bright Minds Biosciences in the 2nd quarter valued at approximately $66,000. New York State Common Retirement Fund bought a new position in shares of Bright Minds Biosciences in the second quarter valued at $107,000. Finally, BNP Paribas Financial Markets increased its holdings in Bright Minds Biosciences by 949.5% during the third quarter. BNP Paribas Financial Markets now owns 4,796 shares of the company’s stock worth $291,000 after buying an additional 4,339 shares during the last quarter. Institutional investors own 40.52% of the company’s stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.